Unnamed: 0,title,date,stock,sentiment
823634.0,Why MacroGenics Is Moving Today,2020-06-05 11:18:00-04:00,MGNX,neutral
823635.0,MacroGenics shares are trading higher after the company announced the FDA has granted Orphan Drug Designation to Margetuximab in the US for gastric cancer.,2020-06-05 07:48:00-04:00,MGNX,negative
823636.0,MacroGenics Announces Margetuximab Granted Orphan Drug Designation In The US For Gastric Cancer,2020-06-05 07:30:00-04:00,MGNX,negative
823637.0,MacroGenics Highlights Publication In Science Translational Medicine Supporting Flotetuzumab Pivotal Study In Patients With Refractory Acute Myeloid Leukemia,2020-06-03 16:07:00-04:00,MGNX,positive
823638.0,"Benzinga's Top Upgrades, Downgrades For June 1, 2020",2020-06-01 09:42:00-04:00,MGNX,positive
823639.0,Macrogenics shares are trading higher after Guggenheim upgraded the company's stock from Neutral to Buy.,2020-06-01 07:36:00-04:00,MGNX,positive
823640.0,Guggenheim Upgrades Macrogenics to Buy,2020-06-01 06:45:00-04:00,MGNX,neutral
823641.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,MGNX,neutral
823642.0,"SVB Leerink Maintains Outperform on Macrogenics, Raises Price Target to $27",2020-05-29 13:08:00-04:00,MGNX,neutral
823643.0,50 Stocks Moving In Friday's Mid-Day Session,2020-05-29 12:15:00-04:00,MGNX,neutral
823644.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,MGNX,positive
823645.0,"BTIG Maintains Buy on Macrogenics, Raises Price Target to $35",2020-05-28 08:49:00-04:00,MGNX,neutral
823646.0,"MacroGenics Provides Update On FDA Review Of Margetuximab For HER2-Positive Metastatic Breast Cancer; Says Advisory Committee Meeting Not Required, PDUFA Goal Date Unchanged",2020-05-28 07:34:00-04:00,MGNX,negative
823647.0,"MacroGenics Offers Update On FDA Review Of Margetuximab: Says AdCom Meeting Not Required, PDUFA Goal Date Unchanged",2020-05-28 07:33:00-04:00,MGNX,neutral
823648.0,MacroGenics Announces Registration Study Of Flotetuzumab In Patients With Refractory Acute Myeloid Leukemia,2020-05-27 07:31:00-04:00,MGNX,neutral
823649.0,Marcogenics shares are trading higher after HC Wainwright maintained its Buy rating on the stock and raised its price target from $22 to $40 per share.,2020-05-26 09:04:00-04:00,MGNX,positive
823650.0,"HC Wainwright & Co. Maintains Buy on Macrogenics, Raises Price Target to $40",2020-05-26 07:41:00-04:00,MGNX,neutral
823651.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,MGNX,neutral
823652.0,60 Biggest Movers From Yesterday,2020-05-15 04:53:00-04:00,MGNX,neutral
823653.0,5 ASCO Abstracts Moving Biopharma Stocks,2020-05-14 15:17:00-04:00,MGNX,neutral
823654.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-05-14 12:55:00-04:00,MGNX,neutral
823655.0,Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.,2020-05-14 11:18:00-04:00,MGNX,negative
823656.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,MGNX,positive
823657.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-14 07:40:00-04:00,MGNX,neutral
823658.0,32 Stocks Moving in Thursday's Pre-Market Session,2020-05-14 07:15:00-04:00,MGNX,neutral
823659.0,"MacroGenics To Present Prelim. Clinical Results From MGD013, MGC018 At ASCO May 29-31",2020-05-13 17:37:00-04:00,MGNX,neutral
823660.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,MGNX,neutral
823661.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,MGNX,neutral
823662.0,"Credit Suisse Maintains Outperform on Macrogenics, Raises Price Target to $30",2020-05-12 08:09:00-04:00,MGNX,positive
823663.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,MGNX,negative
823664.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-05-12 07:33:00-04:00,MGNX,neutral
823665.0,32 Stocks Moving in Tuesday's Pre-Market Session,2020-05-12 07:16:00-04:00,MGNX,neutral
823666.0,78 Biggest Movers From Yesterday,2020-05-12 05:02:00-04:00,MGNX,neutral
823667.0,84 Biggest Movers From Yesterday,2020-05-08 05:34:00-04:00,MGNX,neutral
823668.0,Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Tops Q1 Estimates,2020-05-07 10:22:00-04:00,MGNX,positive
823669.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,MGNX,negative
823670.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-07 07:32:00-04:00,MGNX,neutral
823671.0,66 Biggest Movers From Yesterday,2020-05-07 05:52:00-04:00,MGNX,neutral
823672.0,Mid-Afternoon Market Update: NASDAQ Jumps Over 100 Points; Nautilus Shares Plummet,2020-05-06 14:35:00-04:00,MGNX,positive
823673.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-06 13:19:00-04:00,MGNX,neutral
823674.0,"MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update",2020-05-06 12:59:00-04:00,MGNX,neutral
823675.0,Mid-Day Market Update: Crude Oil Down 6%; Cars.com Shares Jump On Upbeat Q1 Results,2020-05-06 12:48:00-04:00,MGNX,negative
823676.0,Mid-Morning Market Update: Markets Mixed; General Motors Beats Q1 Views,2020-05-06 10:22:00-04:00,MGNX,neutral
823677.0,Macrogenics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-06 09:55:00-04:00,MGNX,positive
823678.0,"Credit Suisse Maintains Outperform on Macrogenics, Lowers Price Target to $13",2020-05-06 09:01:00-04:00,MGNX,positive
823679.0,"HC Wainwright & Co. Reiterates Buy on Macrogenics, Raises Price Target to $22",2020-05-06 07:09:00-04:00,MGNX,neutral
823680.0,"SVB Leerink Reiterates Outperform on Macrogenics, Lowers Price Target to $15",2020-05-06 07:05:00-04:00,MGNX,negative
823681.0,"Macrogenics Q1 EPS $(0.910) Beats $(1.020) Estimate, Sales $13.682M Beat $9.540M Estimate",2020-05-05 16:09:00-04:00,MGNX,neutral
823682.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,MGNX,positive
823683.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,MGNX,neutral
823684.0,MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting,2020-04-27 05:43:00-04:00,MGNX,neutral
823685.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,MGNX,neutral
823686.0,17 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-04-14 07:57:00-04:00,MGNX,neutral
823687.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,MGNX,neutral
823688.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,MGNX,negative
823689.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,MGNX,negative
823690.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,MGNX,negative
823691.0,"The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19",2020-03-05 08:05:00-05:00,MGNX,negative
823692.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,MGNX,positive
823693.0,"Barclays Initiates Coverage On Macrogenics with Underweight Rating, Announces $8 Price Target",2020-03-04 05:32:00-05:00,MGNX,neutral
823694.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,MGNX,neutral
823695.0,140 Biggest Movers From Yesterday,2020-02-28 05:00:00-05:00,MGNX,neutral
823696.0,95 Biggest Movers From Yesterday,2020-02-27 05:18:00-05:00,MGNX,neutral
823697.0,"Stifel Maintains Buy on Macrogenics, Lowers Price Target to $20",2020-02-26 10:17:00-05:00,MGNX,negative
823698.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,MGNX,negative
823699.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,MGNX,neutral
823700.0,"Wedbush Maintains Outperform on Macrogenics, Raises Price Target to $16",2020-01-21 08:03:00-05:00,MGNX,neutral
823701.0,"Macrogenics Estimated Cash, Cash Equivalents And Marketable Securities Balance As Of Dec 31, 2019 Was About $215M",2020-01-09 16:39:00-05:00,MGNX,positive
823702.0,MacroGenics Outlines Corporate Priorities For 2020; Will Discontinue MGD009 And MGD007 Programs,2020-01-09 16:34:00-05:00,MGNX,neutral
823703.0,Macrogenics Files For $250M Mixed Shelf Offering,2019-12-23 16:37:00-05:00,MGNX,neutral
823704.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-20 08:19:00-05:00,MGNX,neutral
823705.0,MacroGenics Announces Submission Of Margetuximab Biologics License Application To US FDA,2019-12-19 12:01:00-05:00,MGNX,neutral
823706.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2019",2019-12-19 09:51:00-05:00,MGNX,positive
823707.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,MGNX,neutral
823708.0,"Cantor Fitzgerald Initiates Coverage On Macrogenics with Overweight Rating, Announces $17 Price Target",2019-12-19 06:23:00-05:00,MGNX,negative
823709.0,8 Biotech Stocks Morgan Stanley Recommends For 2020,2019-12-17 18:27:00-05:00,MGNX,positive
823710.0,"MacroGenics Shares Resume Trade, Rebound Sharply From Low, Now Positive; Stock Up 3% For Session",2019-12-11 10:18:00-05:00,MGNX,positive
823711.0,"MacroGenics Shares Resume Trade, Continue Lower, Now Down 14% For Session",2019-12-11 10:12:00-05:00,MGNX,neutral
823712.0,MacroGenics Shares To Resume Trade At 10:11:48 a.m. EST,2019-12-11 10:07:00-05:00,MGNX,positive
823713.0,"MacroGenics Shares Resume Trade, Fall To Session Low, Now Down 10.7% For Session, Immediately Halted On Second Circuit Breaker",2019-12-11 10:07:00-05:00,MGNX,neutral
823714.0,MacroGenics Highlights Presentation Of Results From SOPHIA Study Of Margetuximab In Patients With HER2-Positive Metastatic Breast Cancer At San Antonio Breast Cancer Symposium,2019-12-11 10:04:00-05:00,MGNX,negative
823715.0,Macrogenics Shares Halted On Circuit Breaker,2019-12-11 10:02:00-05:00,MGNX,positive
823716.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,MGNX,negative
823717.0,MacroGenics Highlights Presentation Of Floteztuzumab Data At ASH,2019-12-09 15:10:00-05:00,MGNX,neutral
823718.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,MGNX,positive
823719.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,MGNX,positive
823720.0,45 Stocks Moving In Thursday's Mid-Day Session,2019-11-21 12:11:00-05:00,MGNX,neutral
823721.0,"UPDATE: Morgan Stanley On MacroGenics Notes 'Despite positive trends, we see F-allele data as unlikely to be on label. MGNX has a broad pipeline but we need to see more data before gaining confidence'",2019-11-21 12:08:00-05:00,MGNX,positive
823722.0,"UPDATE: Morgan Stanley Downgrades MacroGenics To Underweight, Lowers Tgt From $17 To $6 Notes 'Margetuximab is expected to be approved but with limited market opportunity in 4L+ patients'",2019-11-21 12:08:00-05:00,MGNX,positive
823723.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-21 11:09:00-05:00,MGNX,negative
823724.0,"Benzinga's Top Upgrades, Downgrades For November 21, 2019",2019-11-21 09:44:00-05:00,MGNX,positive
823725.0,Macrogenics shares are trading lower after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and announced a price target of $6 per share.,2019-11-21 08:39:00-05:00,MGNX,positive
823726.0,"Morgan Stanley Downgrades Macrogenics to Underweight, Announces $6 Price Target",2019-11-21 06:48:00-05:00,MGNX,neutral
823727.0,Guggenheim Assumes Macrogenics at Neutral,2019-11-20 08:02:00-05:00,MGNX,neutral
823728.0,Stocks That Hit 52-Week Lows On Monday,2019-11-11 10:45:00-05:00,MGNX,negative
823729.0,"Stifel Nicolaus Maintains Buy on Macrogenics, Lowers Price Target to $21",2019-11-07 12:06:00-05:00,MGNX,negative
823730.0,"Citi Maintains Buy on Macrogenics, Lowers Price Target to $18",2019-11-07 06:53:00-05:00,MGNX,negative
823731.0,"Macrogenics Q3 EPS $(0.91) Beats $(0.98) Estimate, Sales $18.741M Miss $19.12M Estimate",2019-11-06 16:27:00-05:00,MGNX,negative
823732.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,MGNX,positive
823733.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,MGNX,neutral
823734.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,MGNX,positive
823735.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-30 10:38:00-04:00,MGNX,negative
823736.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,MGNX,negative
823737.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-29 10:53:00-04:00,MGNX,negative
823738.0,Stocks That Hit 52-Week Lows On Friday,2019-10-25 12:49:00-04:00,MGNX,negative
823739.0,Zai Lab Highlights Partner MagcroGenics Initiated Phase 2/3 Trial Of Margetuximab,2019-10-25 08:33:00-04:00,MGNX,neutral
823740.0,MacroGenics Announces Initiation Of Phase 2/3 MAHOGANY Study Of Margetuximab In Gastric Or Gastroesophageal Junction Cancer.,2019-10-25 07:32:00-04:00,MGNX,negative
823741.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,MGNX,positive
823742.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,MGNX,neutral
823743.0,41 Biggest Movers From Yesterday,2019-10-24 04:25:00-04:00,MGNX,neutral
823744.0,26 Stocks Moving In Wednesday's Mid-Day Session,2019-10-23 12:13:00-04:00,MGNX,neutral
823745.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-23 11:19:00-04:00,MGNX,negative
823746.0,14 Stocks Moving in Wednesday's Pre-Market Session,2019-10-23 08:51:00-04:00,MGNX,neutral
823747.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,MGNX,negative
823748.0,"Wedbush Maintains Outperform on Macrogenics, Lowers Price Target to $14",2019-10-23 07:36:00-04:00,MGNX,negative
823749.0,MacroGenics Announces Second Interim Overall Survival Data From Phase 3 SOPHIA Study Of Margetuximab In Patients With HER2-Positive Metastatic Breast Cancer,2019-10-22 16:33:00-04:00,MGNX,negative
823750.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,MGNX,negative
823751.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,MGNX,neutral
823752.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,MGNX,negative
823753.0,"MacroGenics To Terminate Collaboration Agreement With Laboratoires Servier, Co. To Regain Full Global Rights To Develop And Commercialize Flotetuzumab",2019-07-17 16:24:00-04:00,MGNX,positive
823754.0,"The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug",2019-07-11 06:17:00-04:00,MGNX,neutral
823755.0,MacroGenics And I-Mab Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Enoblituzumab In Greater China,2019-07-10 16:12:00-04:00,MGNX,positive
823756.0,54 Biggest Movers From Yesterday,2019-06-05 06:14:00-04:00,MGNX,neutral
823757.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,MGNX,negative
823758.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,MGNX,neutral
823759.0,Najarian on CNBC he is long Macrogenics and into ASCO Conference,2019-05-31 13:02:00-04:00,MGNX,neutral
823760.0,63 Biggest Movers From Yesterday,2019-05-17 05:05:00-04:00,MGNX,neutral
823761.0,5 ASCO Abstracts That Moved Stocks,2019-05-16 14:50:00-04:00,MGNX,neutral
823762.0,Mid-Afternoon Market Update: KEMET Jumps On Upbeat Q4 Results; EDAP Shares Plunge,2019-05-16 14:38:00-04:00,MGNX,positive
823763.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-05-16 12:36:00-04:00,MGNX,neutral
823764.0,Mid-Day Market Update: Crude Oil Up Over 2%; Virtusa Shares Drop Following Downbeat Q4 Earnings,2019-05-16 12:18:00-04:00,MGNX,negative
823765.0,Macrogenics shares are trading higher after the company reported its SOPHIA Study met its primary endpoint.,2019-05-16 09:19:00-04:00,MGNX,positive
823766.0,"The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics",2019-05-16 07:40:00-04:00,MGNX,neutral
823767.0,MacroGenetics shares are trading higher after the company reported SOPHIA study met its primary endpoint.,2019-05-15 17:27:00-04:00,MGNX,positive
823768.0,UPDATE: MacroGenics Says SOPHIA Study Met Primary Endpoint,2019-05-15 17:15:00-04:00,MGNX,neutral
823769.0,MacroGenics Reports Results From Phase 3 SOPHIA Study Of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer,2019-05-15 17:11:00-04:00,MGNX,negative
823770.0,Macrogenics Option Alert: Jun 21 $20 Calls at the Ask: 2416 @ $1.15 vs 221 OI; Ref=$15.74,2019-05-15 10:55:00-04:00,MGNX,positive
823771.0,"UPDATE: Wedbush Upgrades MacroGenics To Outperform As Firm Believes 'current share price levels provide upside, given potential positive catalysts ahead with updated SOPHIA data at ASCO, and the possibility of a partnership agreement for margetuximab'",2019-05-03 12:23:00-04:00,MGNX,positive
823772.0,MacroGenics shares are trading higher due to Wedbush upgrading the company from Neutral to Outperform.,2019-05-03 11:20:00-04:00,MGNX,positive
823773.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2019",2019-05-03 08:53:00-04:00,MGNX,positive
823774.0,"Wedbush Upgrades MacroGenics, Inc. - Common Stock to Outperform, Announces $26 Price Target",2019-05-03 08:12:00-04:00,MGNX,neutral
823775.0,"Macrogenics Q1 EPS $(0.99) Misses $(0.86) Estimate, Sales $9.7M Miss $18.8M Estimate; Announces Oral Presentation Of Sophia Data At ASCO, Plans To Submit BLA In 2H2019",2019-05-01 16:42:00-04:00,MGNX,negative
823776.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,MGNX,neutral
823777.0,"Credit Suisse Initiates Coverage On Macrogenics with Outperform Rating, Announces $29 Price Target",2019-04-17 08:17:00-04:00,MGNX,positive
823778.0,Guggenheim Initiates Coverage On Macrogenics with Neutral Rating,2019-04-12 07:48:00-04:00,MGNX,neutral
823779.0,MacroGenics Highlights Presentation Of Data At The AACR Annual Meeting 2019,2019-04-03 16:31:00-04:00,MGNX,neutral
823780.0,"Macrogenics Q4 EPS $(1.06) Misses $(1.02) Estimate, Sales $15.794M Beat $10.67M Estimate",2019-02-26 17:35:00-05:00,MGNX,negative
823781.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,MGNX,positive
823782.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,MGNX,neutral
823783.0,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering",2019-02-13 07:49:00-05:00,MGNX,negative
823784.0,MacroGenics Prices 5.5M Share Public Offering of Common Stock @$20/Share,2019-02-12 21:26:00-05:00,MGNX,positive
823785.0,MacroGenics Reports Common Stock Offering; Size Not Disclosed,2019-02-12 16:02:00-05:00,MGNX,neutral
823786.0,72 Biggest Movers From Yesterday,2019-02-08 05:18:00-05:00,MGNX,neutral
823787.0,8 Biggest Price Target Changes For Thursday,2019-02-07 09:49:00-05:00,MGNX,neutral
823788.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2019",2019-02-07 09:05:00-05:00,MGNX,positive
823789.0,"UPDATE: Wedbush Downgrades MacroGenics To Neutral And Raises Price Target From $20 To $26 As Firm Awaits 'the presentation of a more detailed dataset at a medical meeting later this half, particularly regarding PFS duration'",2019-02-07 08:52:00-05:00,MGNX,positive
823790.0,Wedbush Downgrades Macrogenics to Neutral,2019-02-07 08:28:00-05:00,MGNX,neutral
823791.0,26 Stocks Moving In Thursday's Pre-Market Session,2019-02-07 08:10:00-05:00,MGNX,neutral
823792.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,MGNX,neutral
823793.0,Raymond James Upgrades Macrogenics to Market Perform,2019-02-07 07:23:00-05:00,MGNX,neutral
823794.0,"Citigroup Upgrades Macrogenics to Buy, Raises Price Target to $39",2019-02-07 06:26:00-05:00,MGNX,neutral
823795.0,62 Biggest Movers From Yesterday,2019-02-07 04:19:00-05:00,MGNX,neutral
823796.0,Mid-Afternoon Market Update: Container Store Drops On Earnings Miss; MacroGenics Shares Climb,2019-02-06 14:33:00-05:00,MGNX,positive
823797.0,Hearing Raymond James Upgraded Macrogenics From Underperform To Market Perform; Unconfirmed,2019-02-06 14:19:00-05:00,MGNX,negative
823798.0,Macrogenics Option Alert: Jul 19 $30 Calls Sweep (2) near the Bid: 1857 @ $3.3 vs 24 OI; Earnings 2/26 After Close [est] Ref=$25.095,2019-02-06 13:58:00-05:00,MGNX,positive
823799.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-02-06 12:18:00-05:00,MGNX,neutral
823800.0,Mid-Day Market Update: Snap Surges After Strong Q4 Results; Arlo Technologies Shares Slide,2019-02-06 12:00:00-05:00,MGNX,positive
823801.0,"H.C. Wainwright Raises MacroGenics Price Target From $34 To $39 Reiterates Buy As Firm Notes 'With a PFS win and OS trending positive, we anticipate BLA approval during 2H20'",2019-02-06 11:26:00-05:00,MGNX,positive
823802.0,Mid-Morning Market Update: Markets Open Lower; General Motors Earnings Beat Estimates,2019-02-06 10:39:00-05:00,MGNX,negative
823803.0,MacroGenics shares are trading higher after the company announced positive results from its phase 3 SOPHIA study of margetuximab.,2019-02-06 08:51:00-05:00,MGNX,positive
823804.0,33 Stocks Moving In Wednesday's Pre-Market Session,2019-02-06 08:27:00-05:00,MGNX,neutral
823805.0,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,2019-02-06 06:29:00-05:00,MGNX,neutral
823806.0,MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab,2019-02-06 06:06:00-05:00,MGNX,positive
823807.0,Mid-Morning Market Update: Markets Mixed; Clorox Profit Tops Expectations,2019-02-04 10:14:00-05:00,MGNX,positive
823808.0,7 Biggest Price Target Changes For Monday,2019-02-04 09:52:00-05:00,MGNX,neutral
823809.0,Macrogenics shares are trading lower after Citigroup downgraded the stock from Neutral to Sell and lowered the price target from $22 to $10.,2019-02-04 09:38:00-05:00,MGNX,negative
823810.0,"Benzinga's Top Upgrades, Downgrades For February 4, 2019",2019-02-04 09:09:00-05:00,MGNX,positive
823811.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,MGNX,neutral
823812.0,"Citigroup Downgrades Macrogenics to Sell, Lowers Price Target to $10",2019-02-04 06:50:00-05:00,MGNX,negative
823813.0,Macrogenics Option Alert: Feb 15 $15 Calls at the Ask: 500 @ $0.95 vs 19 OI; Earnings 2/26 After Close [est] Ref=$11.7,2019-01-31 12:50:00-05:00,MGNX,positive
823814.0,Macrogenix shares are trading higher after the FDA lifted its partial clinical hold on the company's MGD009 program.,2019-01-25 13:01:00-05:00,MGNX,positive
823815.0,MacroGenics Announces Removal Of Partial Clinical Hold On MGD009 Program By FDA,2019-01-25 13:00:00-05:00,MGNX,neutral
823816.0,"Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019",2019-01-24 10:05:00-05:00,MGNX,negative
823817.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,MGNX,neutral
823818.0,46 Biggest Movers From Yesterday,2018-12-11 05:15:00-05:00,MGNX,neutral
823819.0,Mid-Afternoon Market Update: Crude Oil Down 2%; Veritone Shares Jump,2018-12-10 14:39:00-05:00,MGNX,negative
823820.0,38 Stocks Moving In Monday's Mid-Day Session,2018-12-10 12:37:00-05:00,MGNX,neutral
823821.0,Mid-Day Market Update: Down Down 350 Points; Xperi Shares Spike Higher,2018-12-10 12:07:00-05:00,MGNX,positive
823822.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,MGNX,negative
823823.0,Mid-Morning Market Update: Markets Open Lower; Tivity Health To Acquire Nutrisystem,2018-12-10 10:14:00-05:00,MGNX,negative
823824.0,Macrogenics shares are trading lower after the company late Friday reported a clinical hold on its Plase 1 study of MGD009 due to adverse events in the trial.,2018-12-10 09:27:00-05:00,MGNX,negative
823825.0,31 Stocks Moving In Monday's Pre-Market Session,2018-12-10 08:16:00-05:00,MGNX,neutral
823826.0,"6 Stocks To Watch For December 10, 2018",2018-12-10 05:23:00-05:00,MGNX,neutral
823827.0,Macrogenics Shares To Resume Trade At 4:30 p.m. EST,2018-12-07 16:05:00-05:00,MGNX,positive
823828.0,UPDATE: MacroGenics Initiated Partial Clinical Hold On MGD009 Phase 1 Studies Following Hepatic Adverse Events In MGD009 Trial,2018-12-07 16:04:00-05:00,MGNX,negative
823829.0,MacroGenics Announces Partial Clinical Hold On MGD009 Phase 1 Studies,2018-12-07 16:01:00-05:00,MGNX,neutral
823830.0,Macrogenics Shares Halted News Pending,2018-12-07 16:00:00-05:00,MGNX,positive
823831.0,"Trianni, Inc. and MacroGenics, Inc. Announce License Agreement For Trianni Mouse; Financial Terms Not Disclosed",2018-12-06 13:33:00-05:00,MGNX,positive
823832.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,MGNX,neutral
823833.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,MGNX,neutral
823834.0,"UPDATE: MacroGenics To Receive $25M Upfront Cash Payment, Potential Future Milestones, Royalties Up To $140M",2018-11-29 07:35:00-05:00,MGNX,neutral
823835.0,"MacroGenics Reports Exclusive Collaboration, License Deal With Zai Lab For Development, Commercialization Of Margetuximab, MGD013, TRIDENT Molecule In Greater China",2018-11-29 07:34:00-05:00,MGNX,positive
823836.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,MGNX,neutral
823837.0,"Macrogenics Q3 EPS $(0.81) Beats $(1.32) Estimate, Sales $20.798M Beat $5.04M Estimate",2018-11-07 16:43:00-05:00,MGNX,neutral
823838.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,MGNX,negative
823839.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,MGNX,neutral
823840.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,MGNX,negative
823841.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,MGNX,negative
823842.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,MGNX,negative
823843.0,NanoString Technologies and MacroGenics Announce a Research Agreement to Identify Biomarkers for MacroGenic's MGD013,2018-10-29 06:11:00-04:00,MGNX,positive
823844.0,"BTIG Research Assumes Macrogenics at Buy, Announces Price Target $30",2018-09-10 07:11:00-04:00,MGNX,neutral
823845.0,"Macrogenics Q2 EPS $(1.03) Beats $(1.22) Estimate, Sales $18.83M May Not Compare To $4.21M Estimate",2018-08-07 16:25:00-04:00,MGNX,neutral
823846.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,MGNX,negative
823847.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,MGNX,negative
823848.0,"Evercore ISI Group Initiates Coverage On Macrogenics with Outperform Rating, Announces $33 Price Target",2018-05-31 09:15:00-04:00,MGNX,neutral
823849.0,53 Biggest Movers From Yesterday,2018-05-09 05:37:00-04:00,MGNX,neutral
823850.0,36 Stocks Moving In Tuesday's Mid-Day Session,2018-05-08 14:26:00-04:00,MGNX,neutral
823851.0,"Macrogenics Q1 EPS $(1.34) Misses $(1.08) Estimate, Sales $4.695M Miss $6.79M Estimate",2018-05-07 16:03:00-04:00,MGNX,negative
823852.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,MGNX,neutral
823853.0,28 Stocks Moving In Wednesday's Pre-Market Session,2018-03-28 08:19:00-04:00,MGNX,neutral
823854.0,MacroGenics Prices 4.5M Share Offering At $21.25/Share,2018-03-28 07:30:00-04:00,MGNX,positive
823855.0,38 Biggest Movers From Yesterday,2018-03-28 05:19:00-04:00,MGNX,neutral
823856.0,MacroGenics Shares Down 12.4% After Co.  Monday Announced 4.5M Share Common Stock Offering,2018-03-27 13:19:00-04:00,MGNX,positive
823857.0,30 Stocks Moving In Tuesday's Mid-Day Session,2018-03-27 12:31:00-04:00,MGNX,neutral
823858.0,MacroGenics Reports Offering Of 4.5M Shares Of Common Stock,2018-03-26 16:01:00-04:00,MGNX,positive
823859.0,32 Biggest Movers From Yesterday,2018-03-06 05:08:00-05:00,MGNX,neutral
823860.0,28 Stocks Moving In Monday's Mid-Day Session,2018-03-05 12:32:00-05:00,MGNX,neutral
823861.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2018",2018-03-05 09:13:00-05:00,MGNX,positive
823862.0,"H.C. Wainwright Initiates Coverage On Macrogenics with Buy Rating, Announces $38.00 Price Target",2018-03-05 07:17:00-05:00,MGNX,neutral
823863.0,"Macrogenics Reports FY17 Net Loss $19.6M vs $58.5M In FY16, Sales $157.7M vs $91.9M Last Year",2018-02-27 16:42:00-05:00,MGNX,negative
823864.0,42 Biggest Movers From Yesterday,2018-01-25 05:22:00-05:00,MGNX,neutral
823865.0,MacroGenix Shares Up 16.59% After Tuesday Reporting Continuation Of SOPHIA Study Of Margetuximab,2018-01-24 13:59:00-05:00,MGNX,positive
823866.0,MacroGenics Reports Continuation Of SOPHIA Study Of Margetuximab Based On Completion Of Interim Futility Analysis,2018-01-23 16:31:00-05:00,MGNX,neutral
823867.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,MGNX,neutral
823868.0,23 Stocks Moving In Friday's Pre-Market Session,2018-01-05 08:30:00-05:00,MGNX,neutral
823869.0,MacroGenics Reports Research Collaboration Deal With Roche For Development Of Novel Bispecific Molecule,2018-01-04 07:31:00-05:00,MGNX,positive
823870.0,"MacroGenics Reports Q3 EPS $(1.28) vs $(1.09) Est., Sales $1.663M vs $4.11M Est.",2017-11-08 16:48:00-05:00,MGNX,neutral
823871.0,36 Biggest Movers From Yesterday,2017-10-26 05:10:00-04:00,MGNX,neutral
823872.0,Mid-Afternoon Market Update: Acadia Healthcare Tumbles After Downbeat Results; MacroGenics Shares Surge,2017-10-25 14:34:00-04:00,MGNX,positive
823873.0,36 Stocks Moving In Wednesday's Mid-Day Session,2017-10-25 12:45:00-04:00,MGNX,neutral
823874.0,Mid-Day Market Update: Dow Falls Over 100 Points; Chipotle Shares Drop On Earnings Miss,2017-10-25 12:02:00-04:00,MGNX,negative
823875.0,Incyte and MacroGenics Announce Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012,2017-10-25 06:52:00-04:00,MGNX,positive
823876.0,"MacroGenics Presents Phase 1 Data for Flotetuzumab,  CD123 x CD3 DART Molecule at ESMO 2017",2017-09-10 09:41:00-04:00,MGNX,neutral
823877.0,"Macrogenics Reports the NIAID To Exercise First Of 2 Options Under HIV Contract, Funding MDG014 Into Phase 1 Trials",2017-09-05 16:36:00-04:00,MGNX,neutral
823878.0,"MacroGenics Reports First Pateint Dosed With MGD013, Submission of IND With The FDA For MGD014",2017-09-05 16:32:00-04:00,MGNX,neutral
823879.0,12 Biggest Mid-Day Losers For Friday,2017-09-01 13:14:00-04:00,MGNX,negative
823880.0,Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge,2017-09-01 12:00:00-04:00,MGNX,positive
823881.0,Mid-Morning Market Update: Markets Mostly Higher; Lululemon Beats Q2 Estimates,2017-09-01 10:19:00-04:00,MGNX,neutral
823882.0,"MacroGenics Reports Termination Of Duvortuxizumab Collab., License Deal With J&J's Janssen",2017-08-31 16:30:00-04:00,MGNX,neutral
823883.0,"MacroGenics Reports Q2 EPS $(1.14) vs $(0.83) Est., Sales $1.666M vs $12.44M Est.",2017-08-02 16:31:00-04:00,MGNX,neutral
823884.0,MacroGenics Reports Single Dose Administration of MGD010 Delivers Immunomodulatory Effect that Counters B-cell Function #EULAR2017,2017-06-17 07:45:00-04:00,MGNX,neutral
823885.0,"Macrogenics Reports Q1 EPS $(1.08) vs $(0.97) Est., Sales $2.055M May Not Compare To $5.56M Est.",2017-05-03 16:48:00-04:00,MGNX,neutral
823886.0,MacroGenics Reports Offering of 1.1M Shares at $21.50/Share,2017-04-27 07:25:00-04:00,MGNX,positive
823887.0,"Raymond James Initiates Coverage On Macrogenics With Outperform, Announces $26 Price Target",2017-03-31 09:03:00-04:00,MGNX,neutral
823888.0,Nomura Initiates Coverage On Macrogenics at Buy,2017-03-02 07:26:00-05:00,MGNX,neutral
823889.0,"MacroGenics Reports FY16 EPS $(1.69) vs $(1.61) Est., Sales $91.88M vs $97.42M Est.",2017-02-28 16:26:00-05:00,MGNX,neutral
823890.0,MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA,2017-01-05 16:30:00-05:00,MGNX,positive
823891.0,BB Biotech AG Reports 5.2% Stake In Macrogenics,2016-12-29 15:49:00-05:00,MGNX,neutral
823892.0,"SunTrust Robinson Humphrey Initiates Coverage On Macrogenics at Buy, Announces $30.00 Target",2016-12-19 18:08:00-05:00,MGNX,neutral
823893.0,"MacroGenics Licenses Synthon's Technology to Develop an Anti-B7-H3 ADC, Terms Not Disclosed",2016-12-12 16:32:00-05:00,MGNX,neutral
823894.0,"MacroGenics Reports Q3 EPS $(0.97) vs. Est. $(0.80), Rev. $3.255M vs. Est. $12.45M",2016-11-02 16:39:00-04:00,MGNX,neutral
823895.0,Can You Guess This Chart?,2016-10-20 07:28:00-04:00,MGNX,neutral
823896.0,"MacroGenics Names Dr. Ezio Bonvini Chief Scientific Officer, Eric Rissier Chief Business Officer",2016-09-20 16:31:00-04:00,MGNX,neutral
823897.0,Takeda and MacroGenics Reports the Conclusion of their MGD010 License and Option Agreement,2016-09-12 07:07:00-04:00,MGNX,positive
823898.0,"MacroGenetics MGD010 License and Option Agreement Ends, Regains Worldwide Rights",2016-09-12 07:02:00-04:00,MGNX,positive
823899.0,Cowen & Company Initiates Coverage on Macrogenics at Outperform,2016-09-07 06:38:00-04:00,MGNX,neutral
823900.0,"Citigroup Downgrades Macrogenics to Neutral, Raises PT to $32.00",2016-08-04 09:32:00-04:00,MGNX,neutral
823901.0,"MacroGenics Reports Q2 EPS $1.12, Rev. $80.67M",2016-08-03 16:39:00-04:00,MGNX,neutral
823902.0,"MacroGenics Announces Licensing Contract With Janssen, Will Get $75M Upfront Payment",2016-06-28 07:31:00-04:00,MGNX,neutral
823903.0,MacroGenics Reports Data from Phase 1 Study of MGD010 at EULAR: Well Tolerated at All Dose Levels with No Serious Adverse Effects,2016-06-10 06:04:00-04:00,MGNX,negative
823904.0,Midday Gainers In Depth,2016-05-18 13:10:00-04:00,MGNX,neutral
823905.0,10 Stocks Gaining In Wednesday's Pre-Market: Heavy M&A Activity,2016-05-18 09:42:00-04:00,MGNX,positive
823906.0,MacroGenics Enters Collaboration and License Agreement with Janssen for Treatment of Cancer,2016-05-18 06:06:00-04:00,MGNX,negative
823907.0,First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics Of $2M,2016-05-10 07:33:00-04:00,MGNX,neutral
823908.0,MacroGenics Reports Q1 EPS $(0.88) vs. Est. $(0.67),2016-05-04 17:08:00-04:00,MGNX,neutral
823909.0,"BTIG Starts MacroGenics At Buy, Sees 63% Upside",2016-04-07 17:29:00-04:00,MGNX,neutral
823910.0,"BTIG Research Initiates Coverage on Macrogenics at Buy, Announces $35.00 PT",2016-04-07 16:36:00-04:00,MGNX,neutral
823911.0,"MacroGentics To Present 5 Posters At AACR Meeting, 4 Of 5 Posters Refer To Programs Based On MacroGentics Dual-Affinity Re-Targeting Bispecific Technology",2016-03-16 16:33:00-04:00,MGNX,neutral
823912.0,"Director Costa Buys 10,000 Shares of MacroGenics @$17.20/Share -Form 4",2016-03-04 08:13:00-05:00,MGNX,positive
823913.0,Benzinga's Top Initiations,2016-02-25 09:35:00-05:00,MGNX,positive
823914.0,"Morgan Stanley Initiates Coverage on Macrogenics at Equal-weight, Announces $20.00 PT",2016-02-25 05:29:00-05:00,MGNX,neutral
823915.0,Benzinga's Top Initiations,2016-02-18 09:35:00-05:00,MGNX,positive
823916.0,"Janney Capital Initiates Coverage on Macrogenics at Buy, Announces $36.00 PT",2016-02-18 06:40:00-05:00,MGNX,neutral
823917.0,Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab Presented at 30th Annual SITC Meeting 2015,2015-11-07 20:06:00-05:00,MGNX,neutral
823918.0,Publication in PLOS Pathogens Shows the Potential of DART® Molecules for HIV Reservoir Elimination Strategy,2015-11-05 16:32:00-05:00,MGNX,neutral
823919.0,"Macrogenics Reports Q3 EPS $(0.46) May Not Compare $(0.26) Est., Sales $14.7M May Not Compare $27M Est.",2015-11-04 17:59:00-05:00,MGNX,neutral
823920.0,"Macrogenics Regains European, Other Regional Rights to Enoblituzumab",2015-10-28 07:37:00-04:00,MGNX,neutral
823921.0,"8-K from Macrogenics Shows Co. Entered Deal with Natinoal Institute of Allergy, Infectious Diseases for Product Development, Advancement of DART-1, DART-2",2015-09-17 16:12:00-04:00,MGNX,neutral
823922.0,Benzinga's Top Initiations,2015-09-17 09:12:00-04:00,MGNX,positive
823923.0,"Citigroup Initiates Coverage on Macrogenics at Neutral, Announces $31.00 PT",2015-09-17 07:53:00-04:00,MGNX,neutral
823924.0,Market Panic Has Created 'Compelling' Opportunities In Biotech,2015-08-25 13:06:00-04:00,MGNX,positive
823925.0,"Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics",2015-08-25 09:13:00-04:00,MGNX,positive
823926.0,"MGD011 Moves Into Clinical Development, Triggers $10M Milestone Payment",2015-07-28 07:05:00-04:00,MGNX,neutral
823927.0,US Stock Futures Edge Higher; Bank of America Earnings In Focus,2015-07-15 07:07:00-04:00,MGNX,neutral
823928.0,MacroGenics Prices 3.525M Share Offering @$37.00/Share,2015-07-15 04:24:00-04:00,MGNX,positive
823929.0,MacroGenics Reportys  Offering OF 3.25M Shares,2015-07-13 16:01:00-04:00,MGNX,positive
823930.0,MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO,2015-05-30 09:16:00-04:00,MGNX,neutral
823931.0,Biotech Investors: May 29th Could Be A Big Day,2015-04-21 14:39:00-04:00,MGNX,neutral
823932.0,"Macrogenics To Receive $3M Milestone Payment From Topeka, Initiates Phase 1 Study Of MGD010",2015-03-16 15:27:00-04:00,MGNX,neutral
823933.0,MacroGenics Initiates Phase 1 Study Of MGD010 For Autoimmune Disorder Treatment,2015-03-16 07:01:00-04:00,MGNX,negative
823934.0,"MacroGenics Enters Collaboration, License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies, MacroGenics to Receive $50M Upfront License Fee, $75M Equity Investment by JNJ",2014-12-22 06:06:00-05:00,MGNX,positive
823935.0,Benzinga's Volume Movers,2014-12-18 10:20:00-05:00,MGNX,neutral
823936.0,"Roth Capital Adding Macrogenics To ""Focus List"", Maintains Buy Rating With A PT Of $45",2014-12-15 05:49:00-05:00,MGNX,neutral
823937.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,MGNX,neutral
823938.0,UPDATE: Stifel Reiterates On MacroGenics On Strategic Development Shift,2014-11-12 10:05:00-05:00,MGNX,neutral
823939.0,"Stifel Nicolaus Maintains Buy on MacroGenics, Lowers PT to $51.00",2014-11-12 06:54:00-05:00,MGNX,negative
823940.0,Macrogenics Files Up to $150M Mixed Securities Shelf,2014-11-12 06:25:00-05:00,MGNX,positive
823941.0,"MacroGenics Reports Q3 EPS Loss Of $0.14, Sales $18.4M",2014-11-11 16:04:00-05:00,MGNX,negative
823942.0,MacroGenics Reports Q2 EPS Loss $0.44 vs Est. Loss $0.26,2014-08-05 16:08:00-04:00,MGNX,negative
823943.0,"Oppenheimer Initiates Coverage on MacroGenics at Outperform, Announces $48.00 PT",2014-07-11 07:45:00-04:00,MGNX,neutral
823944.0,"Oppenheimer Initiates Coverage on MacroGenics at Outperform, Announces $48.00 PT",2014-07-10 16:50:00-04:00,MGNX,neutral
823945.0,MacroGenics Initiates Phase 1 MGD006 Study,2014-06-19 07:01:00-04:00,MGNX,neutral
823946.0,CMC Biologics Announces Agreement For Clinical Manufacturing With Macrogenics,2014-06-17 07:07:00-04:00,MGNX,positive
823947.0,"Top Healthcare Movers For June 9, 2014",2014-06-09 14:27:00-04:00,MGNX,positive
823948.0,"MacroGenics Shares Up 9+%, Roth Capital Initiated New Buy Rating, $28 Target",2014-06-09 10:08:00-04:00,MGNX,positive
823949.0,MacroGenics To Get $15M Upfront For DART Development,2014-05-27 08:03:00-04:00,MGNX,neutral
823950.0,"CMC Biologics, MacroGenics Announce Process Development and Manufacturing Agreement for Oncology Product Candidate ",2014-05-06 05:26:00-04:00,MGNX,positive
823951.0,MacroGenics to Present Pre-Clinical Data on MGD010 at IMMUNOLOGY 2014,2014-04-28 17:00:00-04:00,MGNX,neutral
823952.0,13G Filing from Point72 Asset Mgmt on MacroGenics Shows 6.6% Stake,2014-04-09 16:32:00-04:00,MGNX,positive
823953.0,MacroGenics Presents Positive Pre-Clinical Data for MGD007 Against Colorectal Cancer Cells at AACR 2014,2014-04-07 05:46:00-04:00,MGNX,negative
823954.0,MacroGenics to Present Pre-clinical Data on MGD007 at AACR Annual Meeting,2014-03-31 08:30:00-04:00,MGNX,neutral
823955.0,"Stifel Nicolaus Maintains Buy on MacroGenics, Raises PT to $53.00",2014-03-21 07:25:00-04:00,MGNX,neutral
823956.0,MacroGenics Appoints Matthew Fust to Its Board of Directors,2014-03-06 07:09:00-05:00,MGNX,neutral
823957.0,"Stifel Nicolaus Maintains Buy on MacroGenics, Raises PT to $51.00",2014-03-05 07:10:00-05:00,MGNX,neutral
823958.0,UPDATE: Bank of America Upgrades MacroGenics on Broad Immunotherapy Pipeline,2014-02-18 08:07:00-05:00,MGNX,neutral
823959.0,"Bank of America Upgrades MacroGenics to Buy, Raises PT to $50.00",2014-02-18 06:59:00-05:00,MGNX,neutral
823960.0,MacroGenics Prices 3M Share Offering at $36.50/Share,2014-02-12 23:07:00-05:00,MGNX,positive
823961.0,Macrogenics Announces 2.5M Share Offering,2014-02-10 16:04:00-05:00,MGNX,positive
823962.0,MacroGenics Announces Proposed 2.5M Share Public Offering of Common Stock,2014-02-10 16:01:00-05:00,MGNX,positive
823963.0,MacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer in PLOS ONE ,2013-12-11 16:16:00-05:00,MGNX,negative
823964.0,UPDATE: Wedbush Initiates Coverage On MacroGenics On Prospects Of Cancer Treatment Drugs,2013-12-04 08:01:00-05:00,MGNX,negative
823965.0,Benzinga's Top Initiations,2013-12-04 07:03:00-05:00,MGNX,positive
823966.0,"Wedbush Initiates Coverage on MacroGenics at Outperform, Announces $70.00 PT",2013-12-04 06:35:00-05:00,MGNX,neutral
823967.0,"Wedbush Initiates Coverage on MacroGenics at Outperform, Announces $70.00 PT",2013-12-03 16:54:00-05:00,MGNX,neutral
823968.0,UPDATE: Bank of America Initiates Coverage on MacroGenics on Multiple Immunotherapy Platforms,2013-11-04 10:33:00-05:00,MGNX,neutral
823969.0,"Stifel Nicolaus Initiates Coverage on MacroGenics at Buy, Announces $35.00 PT",2013-11-04 08:22:00-05:00,MGNX,neutral
823970.0,Benzinga's Top Initiations,2013-11-04 07:49:00-05:00,MGNX,positive
823971.0,"Leerink Swann Initiates Coverage on MacroGenics at Outperform, Announces $34.00 PT",2013-11-04 07:38:00-05:00,MGNX,neutral
823972.0,"Bank of America Initiates Coverage on MacroGenics at Neutral, Announces $30.00 PO",2013-11-04 06:30:00-05:00,MGNX,negative
823973.0,Macrogenics Shares Open for Trade at $24 After Pricing at $16/Share,2013-10-10 10:46:00-04:00,MGNX,positive
823974.0,Macrogenics to Offer 4M Shares in $14-16/Share Range,2013-10-01 12:56:00-04:00,MGNX,positive
823975.0,"MacroGenics Files $60M IPO, Will List on NASDAQ",2013-09-04 17:33:00-04:00,MGNX,neutral
